Manufacturer
Cipla USA., Inc.
85 drugs, 164 product strengths, 24 recalls on record.
Drugs Cipla USA., Inc. makes
Atorvastatin+2.4%Generic · 50 makersPharmacies pay from$0.699 open recallsAlbuterol+0.4%Generic · 42 makersPharmacies pay from$5.543 open recallsAmlodipine-2.6%Generic · 33 makersPharmacies pay from$0.3017 open recallsSertraline+0.8%Generic · 42 makersPharmacies pay from$0.852 open recallsGabapentin+4.5%Generic · 72 makersPharmacies pay from$0.667 open recallsBupropion-0.4%Generic · 62 makersPharmacies pay from$2.113 open recallsEscitalopram-0.9%Generic · 38 makersPharmacies pay from$1.17Pantoprazole+2.7%Generic · 62 makersPharmacies pay from$1.103 open recallsPregabalin+5.4%Generic · 38 makersPharmacies pay from$1.341 open recallDapagliflozin+0.3%Generic · 18 makersPharmacies pay from$4.89Esomeprazole-3.4%Generic · 107 makersPharmacies pay from$3.844 open recallsCelecoxib-1.7%Generic · 51 makersPharmacies pay from$1.852 open recallsOseltamivir+0.2%Generic · 32 makersPharmacies pay from$9.33Liraglutide-6.7%Generic · 11 makersPharmacies pay from$257Limited availability1 open recallTadalafil+12.9%Generic · 39 makersPharmacies pay from$3.23Being discontinued6 open recallsMetoprolol+1.0%Generic · 65 makersPharmacies pay from$0.48Being discontinued9 open recallsMeloxicamNo changeGeneric · 36 makersPharmacies pay from$0.501 open recallCitalopram+2.3%Generic · 30 makersPharmacies pay from$0.86Cyclobenzaprine+0.6%Generic · 54 makersPharmacies pay from$0.521 open recallPravastatin-2.4%Generic · 27 makersPharmacies pay from$1.706 open recallsDiclofenac-1.0%Generic · 150 makersPharmacies pay from$1.89Being discontinued4 open recallsTopiramate+1.5%Generic · 36 makersPharmacies pay from$0.82Diltiazem+1.6%Generic · 34 makersPharmacies pay from$1.52Being discontinued9 open recallsFenofibrate-10.4%Generic · 42 makersPharmacies pay from$2.192 open recallsHydrocortisone-0.5%Generic · 212 makersPharmacies pay from$1.45Being discontinued5 open recallsSumatriptan+3.4%Generic · 39 makersPharmacies pay from$7.60Budesonide+4.1%Generic · 33 makersPharmacies pay from$15.543 open recallsTerbinafine+0.4%Generic · 42 makersPharmacies pay from$4.29Testosterone-3.4%Generic · 29 makersPharmacies pay from$35.2068 open recallsAlendronate+0.3%Generic · 12 makersPharmacies pay from$3.521 open recallRaloxifene-1.3%Generic · 16 makersPharmacies pay from$6.62Emtricitabine / tenofovir disoproxil-0.5%Generic · 23 makersPharmacies pay from$15.79Sevelamer-0.2%Generic · 36 makersPharmacies pay from$6.411 open recallMetaxalone+3.5%Generic · 35 makersPharmacies pay from$14.05Amoxicillin / clavulanate-0.7%Generic · 31 makersPharmacies pay from$6.241 open recallVitamin K1+5.4%Generic · 32 makersPharmacies pay from$279Gemfibrozil-0.3%Generic · 26 makersPharmacies pay from$3.10Being discontinuedHydrochlorothiazide / lisinopril-0.8%Generic · 24 makersPharmacies pay from$0.88Benztropine-1.9%Generic · 22 makersPharmacies pay from$1.91Being discontinuedNabumetone+5.0%Generic · 22 makersPharmacies pay from$4.04Calcium acetate+3.5%Generic · 20 makersPharmacies pay from$5.27Trospium-2.2%Generic · 20 makersPharmacies pay from$6.201 open recallPirfenidone-4.8%Generic · 19 makersPharmacies pay from$19.58Zonisamide-1.1%Generic · 18 makersPharmacies pay from$2.06PaclitaxelGeneric · 19 makersNo weekly priceCyclosporine-0.1%Generic · 14 makersPharmacies pay from$9.934 open recallsOmeprazole / sodium bicarbonate-6.7%Generic · 16 makersPharmacies pay from$8.27Capecitabine-0.4%Generic · 16 makersPharmacies pay from$10.85Tenofovir disoproxil+0.6%Generic · 15 makersPharmacies pay from$8.87Arformoterol+1.2%Generic · 15 makersPharmacies pay from$38.43Albuterol / ipratropium-2.8%Generic · 14 makersPharmacies pay from$6.88Cinacalcet+1.8%Generic · 13 makersPharmacies pay from$12.5720 open recallsDimethyl fumarate-3.0%Generic · 14 makersPharmacies pay from$11.45Darunavir-8.6%Generic · 12 makersPharmacies pay from$33.59Prucalopride-0.9%Generic · 12 makersPharmacies pay from$18.46VigabatrinGeneric · 14 makersNo weekly priceBeing discontinuedNadolol+15.5%Generic · 12 makersPharmacies pay from$3.82Abacavir+1.2%Generic · 12 makersPharmacies pay from$16.57Entecavir+12.6%Generic · 11 makersPharmacies pay from$7.384 open recallsExemestane-15.7%Generic · 11 makersPharmacies pay from$18.91Griseofulvin-2.3%Generic · 10 makersPharmacies pay from$29.58PalonosetronGeneric · 12 makersNo weekly priceBeing discontinuedLeuprolideNo changeGeneric · 10 makersPharmacies pay from$198Being discontinuedVilazodone-2.1%Generic · 9 makersPharmacies pay from$20.73Difluprednate-6.3%Generic · 10 makersPharmacies pay from$45.37Alfuzosin-0.4%Generic · 10 makersPharmacies pay from$3.14Ambrisentan-9.8%Generic · 10 makersPharmacies pay from$217Dihydroergotamine-0.3%Generic · 10 makersPharmacies pay from$2351 open recallFosfomycin+0.6%Generic · 10 makersPharmacies pay from$26.372 open recallsSalmon calcitonin+3.1%Generic · 10 makersPharmacies pay from$49.99Cyclophosphamide+2.4%Generic · 9 makersPharmacies pay from$34.443 open recallsGlucagon-12.8%Generic · 8 makersPharmacies pay from$1341 open recallRitonavir+0.2%Generic · 7 makersPharmacies pay from$18.23Being discontinuedEfavirenz / emtricitabine / tenofovir disoproxil-1.5%Generic · 7 makersPharmacies pay from$33.23Fosinopril+0.4%Generic · 6 makersPharmacies pay from$4.64Darifenacin+11.5%Generic · 6 makersPharmacies pay from$14.46IcatibantGeneric · 7 makersNo weekly priceBeing discontinuedLanthanum carbonate-1.9%Generic · 6 makersPharmacies pay from$93.444 open recallsNintedanib-10.4%Generic · 6 makersPharmacies pay from$362Abacavir / lamivudine-3.5%Generic · 5 makersPharmacies pay from$42.94Efavirenz-6.8%Generic · 5 makersPharmacies pay from$35.68Emtricitabine-0.1%Generic · 2 makersPharmacies pay from$380Being discontinuedFosinopril / hydrochlorothiazide+3.5%Generic · 2 makersPharmacies pay from$17.59Meprobamate+0.5%Generic · 2 makersPharmacies pay from$137LenalidomideGeneric · 2 makersNo weekly price
Recalls
Class IIOngoingOct 14, 2026Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation SpecificationsCipla USA, Inc. · D-0014-2027Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0661-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0675-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0676-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0449-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0450-2026Class IIOngoingApr 22, 2026Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limitCipla USA, Inc. · D-0451-2026Class IIOngoingApr 15, 2026Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.Cipla USA, Inc. · D-0422-2026Class IIOngoingApr 15, 2026Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.Cipla USA, Inc. · D-0423-2026Class IIIOngoingMar 11, 2026Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.Cipla USA, Inc. · D-0381-2026Class IIIOngoingMar 11, 2026Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.Cipla USA, Inc. · D-0382-2026Class IIIOngoingJan 28, 2026Diclofenac Sodium Topical GelFailed PH SpecificationsCipla USA, Inc. · D-0291-2026Class IIOngoingJan 21, 2026Lanreotide InjectionPresence of Particulate Matter.Cipla USA, Inc. · D-0290-2026Class IIOngoingDec 17, 2025Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness testCipla USA, Inc. · D-0217-2026Class IIOngoingDec 17, 2025Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness testCipla USA, Inc. · D-0218-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0224-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0225-2026Class IIOngoingDec 17, 2025Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Cipla USA, Inc. · D-0226-2026Class IIIOngoingAug 27, 2025Albuterol SulfateFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.Cipla USA, Inc. · D-0593-2025Class IIOngoingJul 30, 2025Budesonide Inhalation SuspensionLack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.Cipla USA, Inc. · D-0541-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0043-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0044-2025Class IITerminatedMay 1, 2024Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USPShort fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.Cipla USA, Inc. · D-0471-2024Class ITerminatedJul 19, 2023Albuterol Sulfate Inhalation AerosolDefective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).Cipla USA, Inc. · D-0938-2023
About Cipla USA., Inc.
No comments yet. Questions, tips, what worked for you - start the conversation.